Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 14

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 14
---
 proceeds to be received upon the completion of this offering, if any, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of net proceeds will vary depending on numerous factors, including our ability to obtain additional financing, the relative success and cost of our research, preclinical and clinical development programs, the amount and timing of additional revenues, if any, received from our collaborations and whether we enter into future collaborations. As a result, management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue other clinical trials or preclinical activities if the net proceeds from this offering and our other sources of cash are less than expected. Pending their use, we plan to invest the net proceeds, if any, from this offering in short- and intermediate-term interest-bearing financial assets and certificates of deposit. S-9 DIVIDEND POLICY We have never paid or declared any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. S-10 DILUTION If you invest in our ordinary shares in this offering, your ownership interest will be diluted immediately to the extent of the difference between the price you pay in this offering and the net tangible book value per ordinary share after this offering. Our net tangible book value as of March 31, 2025 was $19.4 million, or $0.43 per ordinary share, based on 45,420,677 ordinary shares then outstanding. After giving effect to the assumed sale by us of 30,000,000 our ordinary shares at an assumed public offering price of $1.835 per share (the closing price of our ordinary shares on May 28, 2025 as reported on Nasdaq), less the estimated commissions and estimated offering expenses payable by us, our adjusted net tangible book value at March 31, 2025 would have been $72.7 million, or $0.96 per ordinary share. This represents an immediate increase in net tangible book value of $0.53 per share to existing shareholders and an immediate dilution of $0.875 per share to new investors in this offering. The following table illustrates this per share dilution.

| Assumed public offering price per share                                            |